ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

Modeling Will Be Used For Other Populations

November 26, 2010

Phase II Study: Proton Therapy Can Have Similar Success Rate, Smaller Level of Risk in Treatment of Hodgkin Lymphoma

July 25, 2014

NCI Letter To Pittsburgh Details Deficiencies In NSABP Operations

April 8, 1994

Cancer Biomarker Research “Piecemeal and Unorganized,” IOM Report Finds.

April 6, 2007

Evaluation Finds OIG Provides PIs With Flexibility

June 14, 1991

In Brief: Calabresi: Rimer: Outstanding ”For NCAB Chair; board Should Maintain Strong Leadership Role

September 23, 1994